EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Optimizing venetoclax duration with hypomethylating agents for newly diagnosed acute myeloid leukemia: impact on response and survival

Anush A Ginosyan, Karam Ashouri, Justin Cheng, Lauren Ford, Mihir Baya, Lucas Humayun, Danielle Hong, Elaine Huang, Grace Kim, Brandon Tang, Brian Hom, Robert Ireland und 5 weitere

Annals of Hematology · 2026

DOI: 10.1007/s00277-026-07219-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2026. Verfasst von Anush A Ginosyan und 16 weiteren Autor:innen. Beteiligte Einrichtung: Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: Bridged Bicyclo Compounds, Heterocyclic, Leukemia, Myeloid, Acute, Sulfonamides, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Southern California.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The addition of venetoclax to hypomethylating agents (HMAs) is standard for older adults with newly diagnosed acute myeloid leukemia (AML). However, prolonged venetoclax (VEN) exposure can cause cytopenias and infections, raising questions about optimal duration. We conducted a single‑center retrospective study of 102 patients treated between 2018 and 2025 with azacitidine or decitabine plus VEN administered for 14 ( n = 22), 21 ( n = 48), or 28 ( n = 32) days per 28‑day cycle. Baseline cytogenetic and molecular profiling, responses by 2022/2024 ELN criteria, measurable residual disease (MRD), cumulative incidence of relapse (CIR), disease‑free survival (DFS), and overall survival (OS) were analyzed using competing‑risks regression and Cox models. Median age was 68 years and patients received a median of 4 cycles. Composite remission (CR/CRi/CRh/MLFS) was 66.7%, with MRD negativity in 75.0% of responders. Remission and MRD negativity rates did not differ significantly across VEN‑duration cohorts. Median OS and DFS were 17.3 and 12.3 months, respectively, with no significant differences in OS, DFS, and CIR between 14‑, 21‑, and 28‑day cohorts. Grade ≥ 3 cytopenias and transfusion independence rates also did not differ significantly. In this cohort, shortening VEN exposure to 14 or 21 days did not show a significant difference in response, survival, relapse risk, and toxicity profiles relative to a 28‑day schedule in our cohort. These findings support further prospective evaluation of reduced VEN durations in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bridged Bicyclo Compounds, HeterocyclicLeukemia, Myeloid, AcuteSulfonamidesAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleAgedRetrospective StudiesMaleAzacitidineDecitabineMiddle AgedAged, 80 and overDisease-Free SurvivalTreatment OutcomeSurvival Rate

Stichwörter der Autor:innen

AMLElderlyHypomethylating agentsSurvival outcomesTreatment durationVenetoclax

Substanzen

Bridged Bicyclo Compounds, HeterocyclicvenetoclaxSulfonamidesAzacitidineDecitabine

Autor:innen und Institutionen

  • Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
  • Department of Pathology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
  • Department of Pharmacy, Norris Comprehensive Cancer Center, University of Southern California (USC), Los Angeles, CA, USA.
  • Jane Anne Nohl Division of Hematology and Center for the study of Blood disease, Division of Hematology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
  • Jane Anne Nohl Division of Hematology and Center for the study of Blood disease, Division of Hematology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. George.yaghmour@med.u…

Förderung

  • University of Southern California

Zitieren

APA

Ginosyan, A. A., Ashouri, K., Cheng, J., Ford, L., Baya, M., Humayun, L., Hong, D., Huang, E., Kim, G., Tang, B., Hom, B., Ireland, R., Siddiqi, I., Ali, A., Woan, K., Tam, E. L., & Yaghmour, G. (2026). Optimizing venetoclax duration with hypomethylating agents for newly diagnosed acute myeloid leukemia: impact on response and survival. Annals of Hematology. https://doi.org/10.1007/s00277-026-07219-2

Vancouver

Ginosyan AA, Ashouri K, Cheng J, Ford L, Baya M, Humayun L, et al. Optimizing venetoclax duration with hypomethylating agents for newly diagnosed acute myeloid leukemia: impact on response and survival. Annals of Hematology. 2026. doi:10.1007/s00277-026-07219-2

BibTeX
@article{Ginosyan2026,
  author = {Ginosyan, Anush A and Ashouri, Karam and Cheng, Justin and Ford, Lauren and Baya, Mihir and Humayun, Lucas and Hong, Danielle and Huang, Elaine and Kim, Grace and Tang, Brandon and Hom, Brian and Ireland, Robert and Siddiqi, Imran and Ali, Amir and Woan, Karrune and Tam, Eric Leon and Yaghmour, George},
  title = {Optimizing venetoclax duration with hypomethylating agents for newly diagnosed acute myeloid leukemia: impact on response and survival},
  journal = {Annals of Hematology},
  year = {2026},
  doi = {10.1007/s00277-026-07219-2}
}
Kostenlos starten →